Browsing: vaccine

This research exemplifies Duke-NUS’s collaborative spirit, combining expertise across disciplines to push the boundaries of medical science. Professor Patrick Tan, Senior Vice-Dean for Research at Duke-NUS, said: “This is a sterling example of how different research programmes within the School come together to tap their various expertise to advance medical knowledge and improve patients’ lives. The team’s valuable insights may one day translate into a new treatment option to control tumour growth or even offer a cure for cancer.”

The Alliance reiterates the imperative of addressing TB as a top global health priority. Alarming figures show that 1.5 million people die from TB-related causes annually, with millions more affected. Urgent concerted efforts are necessary to stem the tide of this relentless disease. The Philippines’ steadfast commitment to TB elimination resonates deeply with its broader public health agenda. This champions the principles of accessible and quality healthcare for all its citizens, regardless of socioeconomic status or geographic location.

The Duke-NUS research team, collaborating with Duke University and the National University of Singapore, conducted a preclinical comparison between nasal and subcutaneous administration of the COVID-19 vaccine. Their findings were published in eBioMedicine. It revealed that the intranasal route not only induces a strong mucosal antibody response but also enhances long-term mucosal and systemic immune protection.

Explore the latest developments in the Philippines’ COVID-19 vaccine distribution as the Department of Health halts procurement amid depleted stocks. Committee inquiries, vaccine-associated controversies, and insights from healthcare professionals shed light on the nation’s challenges and successes. Dive into the complex landscape of the ongoing pandemic, where strategic government decisions play a pivotal role in balancing effectiveness, financial sustainability, and healthcare needs.

In a notable development for the healthcare sector, Hilleman Laboratories has inaugurated a US$20 million vaccine production facility in Singapore.  This facility, located at Depot Road, is poised to play a crucial role in manufacturing and developing vaccines and biologics.